Rybelsus overview
Brand name for oral semaglutide, FDA-approved for type 2 diabetes mellitus. Daily tablet (3, 7, 14 mg).
Rybelsus at a glance
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
Rybelsus is once-daily oral semaglutide for type 2 diabetes. The shared Rybelsus and Ozempic tablets label (effective January 30, 2026) covers blood-sugar control in adults with type 2 diabetes and lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk. FDA’s shortage data mark the original Rybelsus 3, 7 and 14 mg tablets as “to be discontinued” (June 4, 2026 posting). The CMS fact sheet on 2027 negotiated prices lists a $274 Medicare price for a 30-day supply of Rybelsus from January 1, 2027. The Wegovy pill, a different oral semaglutide product, is the one approved for weight management in adults.